Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2017-06-16 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
吉林和泽生物科技有限公司审计报告
Regulatory Filings Classification · 95% confidence The document text is extremely short (136 characters) and contains no substantive content, financial data, or any indication of report type. It only mentions scanning software and omitted pictures, which suggests it is not a financial report or announcement. Given the lack of content, the document does not fit any specific filing category and defaults to Regulatory Filings (RNS) as a fallback category.
2017-06-16 Chinese
海南和泽生物科技有限公司审计报告
Regulatory Filings Classification · 95% confidence The document text is extremely short (136 characters) and contains no substantive content, financial data, or any indication of report type. It only mentions scanning software and omitted pictures, which suggests it is not a report or announcement but rather a placeholder or scanned image note. Given the lack of any meaningful content, the document does not fit any specific report category and defaults to Regulatory Filings (RNS) as a fallback category.
2017-06-16 Chinese
关于法定代表人代行董事会秘书职责的公告
Board/Management Information Classification · 95% confidence The document is a short announcement regarding a change in the company's board secretary duties, specifically about the legal representative acting as the board secretary. It mentions resignation and appointment details but contains no financial data, no report attachments, or regulatory certifications. It is an announcement about management role changes, fitting the Board/Management Information category.
2017-06-16 Chinese
和泽生物科技有限公司拟收购北京天和兴泰投资有限公司持有的海南和泽生物科技有限公司部分股权所涉及的海南和泽生物科技有限公司股东全部权益价值评估报告
Regulatory Filings
2017-06-16 Chinese
安徽和泽华中生物科技有限公司审计报告
Regulatory Filings Classification · 95% confidence The document text is extremely short (136 characters) and contains no substantive content, financial data, or any indication of report type. It only mentions scanning software and omitted pictures, which suggests it is not a financial or regulatory report but rather a placeholder or scanned image notice. Given the lack of content and context, the document does not fit any specific report category and defaults to Regulatory Filings (RNS) as a fallback category.
2017-06-16 Chinese
独立董事关于子公司和泽生物科技有限公司收购其下属子公司少数股东股权事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on a subsidiary acquisition transaction, including assessment of fairness, compliance with laws, and impact on shareholders. It is not a full financial report, earnings release, or regulatory filing but a formal opinion related to a corporate transaction. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is also not a proxy solicitation or voting result announcement. The document is a formal opinion on a transaction, which aligns best with Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2017-06-16 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.